{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:40:50Z","timestamp":1760964050310,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.soc.2022.07.005","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T18:28:19Z","timestamp":1667500099000},"page":"47-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Trials in Melanoma"],"prefix":"10.1016","volume":"32","author":[{"given":"Cimarron E.","family":"Sharon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia M.","family":"Beasley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgos C.","family":"Karakousis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.soc.2022.07.005_bib1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.6004\/jnccn.2019.0018","article-title":"Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Coit","year":"2019","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.soc.2022.07.005_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1245\/s10434-019-07866-y","article-title":"The Landmark Series: Randomized Trials Examining Surgical Margins for Cutaneous Melanoma","volume":"27","author":"Angeles","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.soc.2022.07.005_bib3","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/1097-0142(19840315)53:6<1256::AID-CNCR2820530607>3.0.CO;2-6","article-title":"Conservative surgical management of superficially invasive cutaneous melanoma","volume":"53","author":"Cosimi","year":"1984","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.soc.2022.07.005_bib4","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/1097-0142(197903)43:3<883::AID-CNCR2820430316>3.0.CO;2-V","article-title":"Tumor thickness as a guide to surgical management of clinical stage I melanoma patients","volume":"43","author":"Balch","year":"1979","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.soc.2022.07.005_bib5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1056\/NEJM198202253060810","article-title":"Narrower margins for clinical stage I malignant melanoma","volume":"306","author":"Day","year":"1982","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.soc.2022.07.005_bib6","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1056\/NEJM198805053181804","article-title":"Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3\u00a0cm","volume":"318","author":"Veronesi","year":"1988","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.soc.2022.07.005_bib7","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/archsurg.1991.01410280036004","article-title":"Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma","volume":"126","author":"Veronesi","year":"1991","journal-title":"Arch Surg"},{"issue":"2","key":"10.1016\/j.soc.2022.07.005_bib8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10434-000-0087-9","article-title":"Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0\u00a0mm). Intergroup Melanoma Surgical Trial","volume":"7","author":"Balch","year":"2000","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.soc.2022.07.005_bib9","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/BF02305762","article-title":"Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial","volume":"3","author":"Karakousis","year":"1996","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.soc.2022.07.005_bib10","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/00000658-199309000-00005","article-title":"Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4\u00a0mm). Results of a multi-institutional randomized surgical trial","volume":"218","author":"Balch","year":"1993","journal-title":"Ann Surg"},{"issue":"7","key":"10.1016\/j.soc.2022.07.005_bib11","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/1097-0142(20001001)89:7<1495::AID-CNCR12>3.0.CO;2-D","article-title":"Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0\u00a0mm","volume":"89","author":"Cohn-Cedermark","year":"2000","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.soc.2022.07.005_bib12","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/(SICI)1097-0142(19960501)77:9<1809::AID-CNCR8>3.0.CO;2-6","article-title":"Resection margins of 2 versus 5\u00a0cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0\u00a0mm: randomized study by the Swedish Melanoma Study Group","volume":"77","author":"Ringborg","year":"1996","journal-title":"Cancer"},{"issue":"10197","key":"10.1016\/j.soc.2022.07.005_bib13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0140-6736(19)31132-8","article-title":"2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2\u00a0mm: long-term follow-up of a multicentre, randomised trial","volume":"394","author":"Utj\u00e9s","year":"2019","journal-title":"Lancet"},{"issue":"9803","key":"10.1016\/j.soc.2022.07.005_bib14","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(11)61546-8","article-title":"2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2\u00a0mm: a randomised, multicentre trial","volume":"378","author":"Gillgren","year":"2011","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.soc.2022.07.005_bib15","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/cncr.11272","article-title":"Surgical margins in cutaneous melanoma (2\u00a0cm versus 5\u00a0cm for lesions measuring less than 2.1-mm thick)","volume":"97","author":"Khayat","year":"2003","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.soc.2022.07.005_bib16","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJMoa030681","article-title":"Excision margins in high-risk malignant melanoma","volume":"350","author":"Thomas","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.soc.2022.07.005_bib17","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1470-2045(15)00482-9","article-title":"Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial","volume":"17","author":"Hayes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9105","key":"10.1016\/j.soc.2022.07.005_bib18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(97)08260-3","article-title":"Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme","volume":"351","author":"Cascinelli","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.soc.2022.07.005_bib19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00000658-199609000-00002","article-title":"Efficacy of an elective regional lymph node dissection of 1 to 4\u00a0mm thick melanomas for patients 60 years of age and younger","volume":"224","author":"Balch","year":"1996","journal-title":"Ann Surg"},{"issue":"11","key":"10.1016\/j.soc.2022.07.005_bib20","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/1097-0142(19820601)49:11<2420::AID-CNCR2820491133>3.0.CO;2-2","article-title":"Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities","volume":"49","author":"Veronesi","year":"1982","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.soc.2022.07.005_bib21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1245\/s10434-019-07830-w","article-title":"The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes)","volume":"27","author":"Bello","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"10.1016\/j.soc.2022.07.005_bib22","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1056\/NEJMoa060992","article-title":"Sentinel-node biopsy or nodal observation in melanoma","volume":"355","author":"Morton","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.soc.2022.07.005_bib23","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.soc.2022.07.005_bib24","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","article-title":"Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial","volume":"17","author":"Leiter","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.soc.2022.07.005_bib25","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1245\/s10434-008-0187-5","article-title":"Positive nonsentinel node status predicts mortality in patients with cutaneous melanoma","volume":"16","author":"Ariyan","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"23","key":"10.1016\/j.soc.2022.07.005_bib26","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.soc.2022.07.005_bib27","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3332\/ecancer.2019.961","article-title":"Innovative approaches for cancer treatment: current perspectives and new challenges","volume":"13","author":"Pucci","year":"2019","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.soc.2022.07.005_bib28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J\u00a0Transl Med"},{"issue":"2","key":"10.1016\/j.soc.2022.07.005_bib29","first-page":"24","article-title":"Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research","volume":"3","author":"Bhatia","year":"2015","journal-title":"Ann Transl Med"},{"issue":"12","key":"10.1016\/j.soc.2022.07.005_bib30","first-page":"e3700","article-title":"Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy","volume":"10","author":"Sahni","year":"2018","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.soc.2022.07.005_bib31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1758834015616934","article-title":"Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy","volume":"8","author":"Eroglu","year":"2016","journal-title":"Ther Adv Med Oncol"},{"issue":"26","key":"10.1016\/j.soc.2022.07.005_bib32","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.soc.2022.07.005_bib33","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.2013.49.8691","article-title":"Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma","volume":"31","author":"Ascierto","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"9839","key":"10.1016\/j.soc.2022.07.005_bib34","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.soc.2022.07.005_bib35","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.soc.2022.07.005_bib36","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S1470-2045(18)30106-2","article-title":"Adjuvant vemurafenib in resected, BRAF","volume":"19","author":"Maio","year":"2018","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.soc.2022.07.005_bib37","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.soc.2022.07.005_bib38","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.soc.2022.07.005_bib39","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.soc.2022.07.005_bib40","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10336","key":"10.1016\/j.soc.2022.07.005_bib41","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.soc.2022.07.005_bib42","doi-asserted-by":"crossref","first-page":"9501","DOI":"10.1200\/JCO.2021.39.15_suppl.9501","article-title":"Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pemnbrolizumab in patients with high-risk resected melanoma","author":"Grossman","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.soc.2022.07.005_bib43","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/2159-8290.CD-21-1141","article-title":"Adjuvant Pembrolizumab versus IFN\u03b12b or Ipilimumab in Resected High-Risk Melanoma","volume":"12","author":"Grossmann","year":"2022","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.soc.2022.07.005_bib44","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1245\/s10434-018-6470-1","article-title":"1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study","volume":"25","author":"Moncrieff","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.soc.2022.07.005_bib45","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1245\/s10434-018-6573-8","article-title":"MelMART Trial: It's Now or Never","volume":"25","author":"Coit","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.soc.2022.07.005_bib46","unstructured":"Bristol Myers Squibb. Press release: Bristol-Myers Squibb announces update on CheckMate-915 for Opdivo (nivolumab) plus Yervoy (ipilimumab) versus Opdivo alone in patients with resected high-risk melanoma and PD-L1 <1%. November 20th 2019. Available at: https:\/\/news.bms.com\/news\/details\/2019\/Bristol-Myers-Squibb-Announces-Update-on-CheckMate--915-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Versus-Opdivo-Alone-in-Patients-with-Resected-High-Risk-Melanoma-and-PD-L1-1\/default.aspx."},{"key":"10.1016\/j.soc.2022.07.005_bib47","unstructured":"Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma (NADINA). 2021. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04949113."},{"key":"10.1016\/j.soc.2022.07.005_bib48","unstructured":"A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma. 2018. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03698019."},{"issue":"15_suppl","key":"10.1016\/j.soc.2022.07.005_bib49","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9583","article-title":"Adjuvant nivolumab in high-risk stage IIb\/IIc melanoma patients: Results from investigator initiated clinical trial","volume":"39","author":"Wilson","year":"2021","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320722000552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320722000552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:04:30Z","timestamp":1760961870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320722000552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1055320722000552"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2022.07.005","relation":{},"ISSN":["1055-3207"],"issn-type":[{"type":"print","value":"1055-3207"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Trials in Melanoma","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2022.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}